Barsouk A, Elghawy O, Watts A, Reed-Guy L, et al. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer 2025;203:108551.
PMID: 40262226